drugset / Trial / NCT03715309
R2 in the Treatment of Follicular Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Lenalidomide Based Immunotherapy in the Treatment of FL
Timeline
- Start
- 2018-11-01
- Primary completion
- 2020-11-01
- Completion
- 2020-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |